Challenges with advanced therapy medicinal products and how to meet them. - Wikidata - awgldk - TriplyDB

Challenges with advanced therapy medicinal products and how to meet them.

Challenges with advanced therapy medicinal products and how to meet them.

http://www.wikidata.org/entity/Q45857265

about

Stem Cells in Skin Wound Healing: Are We There Yet?Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation Bioreactor-Based Online Recovery of Human Progenitor Cells with Uncompromised Regenerative Potential: A Bone Tissue Engineering Perspective Keeping an eye on decellularized corneas: a review of methods, characterization and applications.Adaptation through Collaboration: Developing Novel Platforms to Advance the Delivery of Advanced Therapies to Patients.Stem cell trials for cardiovascular medicine: ethical rationale.Deterministic and stochastic approaches in the clinical application of mesenchymal stromal cells (MSCs).Translating research into clinical scale manufacturing of mesenchymal stromal cells.The survey on cellular and engineered tissue therapies in Europe in 2012.Model-based cell number quantification using online single-oxygen sensor data for tissue engineering perfusion bioreactors.Regulations and guidelines governing stem cell based products: Clinical considerations.In question: the scientific value of preclinical safety pharmacology and toxicology studies with cell-based therapies.From banking to international governance: fostering innovation in stem cell research.Cell-assisted lipotransfer.Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP).Clinical development of advanced therapy medicinal products in Europe: evidence that regulators must be proactive Manufacturing of dental pulp cell-based products from human third molars: current strategies and future investigations.Stem cell- and growth factor-based regenerative therapies for avascular necrosis of the femoral head Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development.Concise review: cell therapies: the route to widespread adoption.Concise review: the clinical application of mesenchymal stem cells for musculoskeletal regeneration: current status and perspectives European regulatory tools for advanced therapy medicinal products.Regulatory considerations in production of a cell therapy medicinal product in Europe to clinical research.Development of a cell-based medicinal product: regulatory structures in the European Union.Regenerative medicine interventions for orthopedic disorders: ethical issues in the translation into patients.Concise review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots?White spots in pharmaceutical pipelines-EMA identifies potential areas of unmet medical needs.EATRIS, a vision for translational research in Europe.Are there specific translational challenges in regenerative medicine? Lessons from other fields.Gene delivery to the lungs: pulmonary gene therapy for cystic fibrosis.Growth Factor Content in Human Sera Affects the Isolation of Mesangiogenic Progenitor Cells (MPCs) from Human Bone Marrow.Stem Cells and Tissue Engineering: Regeneration of the Skin and Its Contents.Definition and classification of early osteoarthritis of the knee.Quantitative Validation of the Presto Blue Metabolic Assay for Online Monitoring of Cell Proliferation in a 3D Perfusion Bioreactor System.Anti-Interleukin-6 Promotes Allogeneic Bone Marrow Engraftment and Prolonged Graft Survival in an Irradiation-Free Murine Transplant Model.Advanced Therapy Medicinal Products and Exemptions to the Regulation 1394/2007: How Confident Can We be? An Exploratory Analysis.Three-dimensional characterization of tissue-engineered constructs by contrast-enhanced nanofocus computed tomography.Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe.Accelerating Patients' Access to Advanced Therapies in the EU.Challenges in the development of a reference standard and potency assay for the clinical production of RAFT tissue equivalents for the cornea.

P2860

Q26748513-8EE4BD28-CCD6-4A70-98A1-2467B0F551D1 Q26799437-9541FADB-EA63-42BB-9E5B-CD3EAF8905F2 Q27320859-8BA2A3DE-C455-4565-B3D6-C0725A2DE152 Q30436828-4DA5C664-EF62-4A6A-9697-DAAC1C50F179 Q33734670-D1FDF7D4-B7FA-432D-9103-2C0AC8D8AF2C Q34331206-678F6DDD-D694-429E-A65B-15E686CAC320 Q34391114-876E9482-2758-450B-A95B-091FC3DC49D5 Q34557484-4E5342E9-88FD-48A5-ACC0-D7AF320DD5B0 Q34938449-7475478F-B99A-453B-9F19-D637281CA649 Q35158358-6E16AB81-39FE-44C9-BD68-686884F1401C Q35173932-A202DF98-BD0F-473F-AA70-A2D7BA605786 Q35184210-D85326EC-91C7-4FB6-AC14-489E7FCF18FD Q35196954-5F8FF288-7BC6-47EE-AB4C-C69114959DFA Q35568502-E0263E76-18F5-489A-BA8A-332BDC91AE43 Q35652183-8F1DD515-C25A-4774-BC98-D59CB9BF7FD5 Q35802081-63E908FE-8069-41CF-A1AE-44C32D7995D6 Q35921981-33D302BE-D96C-4141-800E-1FF67155309A Q35923390-0F11F59C-66F5-4342-ADB3-A3CE4DC55DE1 Q36162423-E23BD407-6E14-4831-8AD7-FEB617471B75 Q36861566-CE53BBF8-8921-46BA-8843-FC9153C559AD Q36862085-791D961E-ABCA-4107-B58B-400758A29406 Q37513945-255A2AB1-ABE0-4443-ACAD-8D7F14669999 Q38046738-B1BF8842-222F-48F6-9200-DD4E1A234EAA Q38062899-354E6970-2BA5-4C4F-B0B2-F675DCE45773 Q38069234-F994D6E9-3D30-4C96-869D-D849A2307841 Q38114405-7A680106-079B-4F87-A14F-9092ADE53D05 Q38386799-4AEEB105-592A-4746-B237-62B21CF3FB7B Q38423394-96762207-C0A6-4832-8666-9AEC2EF33EC3 Q38626131-A653CE6C-9158-44B8-8411-590F676E4DE7 Q39166790-65ACFE37-C091-4E12-9E98-4BEEDA8B5735 Q39228638-F7F408EC-C120-4B86-B8A2-87B4DE4B513D Q39347029-80D3DE08-A431-4ED2-ABFE-2F05199EA077 Q39688966-F17C3B57-E44F-4AC9-BABC-4D57401FD3B4 Q41021346-DAD80BF8-8801-4509-ACDD-5613C6C836ED Q41050325-85A3FABD-4EA6-4575-AAFD-72F61BDC036A Q41092191-DC5615E5-2C9C-439C-A4F2-D16FAD963D82 Q41981860-76B5552E-BFBA-466B-B321-9A892885C131 Q42265051-21CE3D9A-9500-4DDA-A7E4-1B9943C4CA73 Q42362633-AB46A767-F978-4FBA-BCFB-DBE51E4CDF81 Q42803695-6EBA9F68-0027-47C7-9B26-1D25322B7162

P2860

Challenges with advanced therapy medicinal products and how to meet them.

http://www.wikidata.org/entity/Q45857265

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Challenges with advanced therapy medicinal products and how to meet them.

@en

Challenges with advanced therapy medicinal products and how to meet them.

@nl

type

label

Challenges with advanced therapy medicinal products and how to meet them.

@en

Challenges with advanced therapy medicinal products and how to meet them.

@nl

prefLabel

Challenges with advanced therapy medicinal products and how to meet them.

@en

Challenges with advanced therapy medicinal products and how to meet them.

@nl

P1433

Q45857265-47C97534-202F-48DC-9B5B-1B357A501C85

P1476

Q45857265-2644D93E-D290-402C-9F9F-F997B813E90D

P2093

Q45857265-00DCB4DB-0467-4E64-B659-EBFC4C7D51EC

Q45857265-06617146-5BEB-4541-9BEF-FEFC953D0102

Q45857265-125264EB-4C44-42FA-9123-5380545E5F05

Q45857265-17DA2ABA-B09D-4A94-8E76-742A49665591

Q45857265-21B31A36-1F60-40F7-B1F5-748054FC8F04

Q45857265-396C896E-03A1-4A4F-896E-79D2041CC82C

Q45857265-3E853FF3-9D6B-49E2-A2A0-8BAEC3478A6A

Q45857265-4AE1B3BB-B472-4519-81A7-262E03ABE2D8

Q45857265-4BE0F37E-F0F4-4888-89F4-026FF0E76FB9

Q45857265-4CA8485A-72B2-4628-84DE-D8AD356AA07E

P2860

Q45857265-64AF3698-D114-4D64-9D50-01756F6D6C96

Q45857265-9A717F4F-5DDB-43E4-B5F1-E6574CB92407

P2888

Q45857265-0E88414B-75EE-403F-996D-7F58E8870AF4

P304

Q45857265-C5084D32-A351-45CE-8521-86D2710CEBFF

P31

Q45857265-CB9D40C0-9992-42DE-BC4F-5F3371A59530

P356

Q45857265-2B58A584-931A-4ECE-A754-7D77C9A7BFD8

P433

Q45857265-4BCB6D33-CE8C-448E-A91D-53A2962E7EAC

P478

Q45857265-F69FDBB9-D5FB-4423-B208-2B9EE3864403

P50

Q45857265-0B2780E2-4602-4266-8736-B77305BAF9CE

Q45857265-5683890D-32B8-4817-8E05-60C1B2506F21

Q45857265-57DA89A0-4413-41EF-973D-A87A3DAC27CF

Q45857265-6A8C91B0-031B-4CA3-801B-529CCEB4BEB6

Q45857265-6D69937F-B6A1-4CE9-938B-73C0D1C0E078

Q45857265-7F7948BC-09DD-4B3D-BF71-F65EF4DD9C5F

Q45857265-A1AFAE5E-919B-48B0-AA36-8BAA749362BC

Q45857265-B7E23D95-7C6A-4CF7-B2E5-9B4D1F294523

P577

Q45857265-AA1CCFBE-C69E-4674-94F1-8AC7C29DAC0A

P5875

Q45857265-1FD9A68F-746E-44B6-9A34-867CC3950B3C

P6179

Q45857265-BE225823-9FA1-4D97-93B6-2B9EC2F17ACF

P698

Q45857265-2CBF4691-CB47-4783-B78B-B80B4DB6BF4F

P356

P1433

Nature Reviews Drug Discovery

P1476

Challenges with advanced therapy medicinal products and how to meet them

@en

P2093

Alastair Kent

http://www.w3.org/2001/XMLSchema#string

Alena Pychova

http://www.w3.org/2001/XMLSchema#string

Anca Stela Moraru

http://www.w3.org/2001/XMLSchema#string

Anna Paphitou

http://www.w3.org/2001/XMLSchema#string

Anthony Samuel

http://www.w3.org/2001/XMLSchema#string

Asterios Tsiftsoglou

http://www.w3.org/2001/XMLSchema#string

Balázs Sarkadi

http://www.w3.org/2001/XMLSchema#string

Beatriz Silva Lima

http://www.w3.org/2001/XMLSchema#string

Bernd Jilma

http://www.w3.org/2001/XMLSchema#string

Bruno Flamion

http://www.w3.org/2001/XMLSchema#string

P2860

Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient

Articular cartilage tissue engineering: today's research, tomorrow's practice?

P2888

P304

195-201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRD3052

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Giovanni Migliaccio

Maria Cristina Galli

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41623367

http://www.w3.org/2001/XMLSchema#string

P6179

1046441802

http://www.w3.org/2001/XMLSchema#string

P698

20190786

http://www.w3.org/2001/XMLSchema#string